Abstracts tagged "prognostic factors"

Abstract Number: 0540 • ACR Convergence 2025
Low-Dose CT reveals syndesmophyte progression in axial SpA, particularly in the thoracic spine: Insights from the SPACE cohort covering early and established disease
Manouk de Hooge¹, Mary Lucy Marques², Gizem Ayan³, Miranda van Lunteren⁴, Liese de Bruin⁴, Monique Reijnierse⁵, Désirée Van Der Heijde⁴, Sofia Ramiro⁶ and Floris A. van Gaalen⁴, ¹Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands; and Coimbra Local Health Unit, Coimbra, Portugal, ³Ankara Research and Training Hospital, Ankara, Turkey, ⁴Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁵Department of Radiology, Leiden University Medical Center, Leiden, Netherlands, ⁶Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: Low-dose computed tomography (ldCT) has not previously been used to assess pt with axial spondyloarthritis (axSpA) early in their disease course, especially those with…
Abstract Number: 2595 • ACR Convergence 2025
Impact of Different Types of Physical Activity on Bone Health in Patients with Inflammatory Rheumatic Diseases: a Cross-Sectional Analysis from a Prospective Cohort Study
Edgar Wiebe¹, Claire-Felicia Liebich², Dörte Huscher³, Lien Meerkatt⁴, Andriko Palmowski⁵, Sandra Hermann¹, Burkhard Muche⁵, Zhivana Boyadzhieva², Gerhard Krönke⁶, Bernd Wolfarth² and FRANK BUTTGEREIT⁷, ¹Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, Berlin, Germany, ²Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Berlin, Germany, ³Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Berlin, Germany, ⁴Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Berlin, Germany, ⁵Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁶Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, Berlin, Germany, ⁷Charité University Medicine Berlin, Berlin, Berlin, Germany
Background/Purpose: Physical exercise helps maintain bone mineral density (BMD), prevent falls, and reduce fracture risk. Strength and weight-bearing exercises are particularly effective. However, individuals with…
Abstract Number: 1212 • ACR Convergence 2025
Relapse in Idiopathic Inflammatory Myopathies: insights from extended MyoCite and Italian Consortia
Maria Rosa Pellico¹, Cristina Bochicchio², Claudia Iannone³, Lekshmi Minikumari Rahulan⁴, Marco Fornaro⁵, Ilaria Cavazzana⁶, Edoardo Conticini⁷, Masataka Kuwana⁸, Akira Yoshida⁹, Silvia Cavalli², Silvia Grazzini⁷, Alessia Gatti¹⁰, Giulio Lopinto¹¹, Paolo Semeraro¹², Thomas Patrick Sheeran¹³, Florenzo Iannone¹⁴, Vikas Agarwal¹⁵, Roberto Caporali¹⁶, Nicoletta Del pAPA¹ and Latika Gupta¹⁷, ¹ASST Pini-CTO, Clinical Rheumatology Unit, Milano, Italy, ²ASST Pini-CTO, Clinical Rheumatology Unit, Milan, Italy, ³University of Milan, Gaetano Pini CTO, Milano, Milan, Italy, ⁴Sanjay Gandhi Postgraduate Institute of Medical sciences Lucknow, Lucknow, Uttar Pradesh, India, ⁵Unit of Rheumatology, Department of Precision and Regenerative Medicine, Area Jonica (DiMePRe-J), University of Bari, Italy., Bari, Italy, ⁶Rheumatology and Clinical Immunology Unit, Clinical and Experimental Sciences Department, ERN ReCONNET, ASST Spedali Civili of Brescia and University of Brescia, Brescia, Italy, Brescia, Lombardia, Italy, ⁷Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Italy, Siena, Italy, ⁸Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ⁹Department of Allergy and Rheumatology Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ¹⁰Rheumatology and Clinical Immunology Unit – ERN ReCONNET, ASST Spedali Civili and University of Brescia, Brescia, Lombardia, Italy, ¹¹Unit of Rheumatology, Department of Precision and Regenerative Medicine, Area Jonica (DiMePRe-J), University of Bari, Italy., Bari, ¹²Rheumatology and Clinical Immunology Unit, Clinical and Experimental Sciences Department, ERN ReCONNET, ASST Spedali Civili of Brescia and University of Brescia, Brescia, Italy, Brescia, Italy, ¹³Department of Rheumatology, The Royal Wolverhampton NHS Trust, Wolverhampton, UK; Rheumatology Department, Walsall Manor Hospital, Walsall, UK, Wolverhampton, United Kingdom, ¹⁴Rheumatology DiMePReJ, University of Bari, School of Medicine, Bari, Italy, Bari, Italy, ¹⁵Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ¹⁶University of Milan and ASST Gaetano Pini-CTO, Milano, Italy, ¹⁷School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham; Royal Wolverhampton NHS Trust; Centre for Musculoskeletal Research, School of Biological Sciences, The University of Manchester, Manchester; Francis Crick Institute, London, Birmingham, UK, United Kingdom
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of rare and heterogeneous diseases. One of the greatest challenges in IIM management is defining and predicting…
Abstract Number: 0511 • ACR Convergence 2025
Submandibular Gland Ratio Stratifies Salivary Function and Reveals a Senescence Peak in Anti-SSA Positive Sjögren’s Syndrome
Chiao-Feng Cheng¹, Tseng-Cheng Chen², Min-Shu Hsieh³, TING-YUAN LAN⁴, Jui-Hung Kao⁵, Yu Heng Lin⁶, Mei-Fang Cheng⁷, Yi-Chieh Chen⁸, Hsiao-Sang Chu⁹, Yi-Min Huang¹⁰, Cheng-Hsun Lu¹¹, Ko-Jen Li¹¹, Chieh-Yu Shen¹ and Song-Chou Hsieh¹², ¹Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, Taipei, Taiwan (Republic of China), ²Department of Otolaryngology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan., Taipei, Taiwan (Republic of China), ³Department of Pathology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei ¹⁰⁰²²⁵, Taiwan, Taipei, Taiwan (Republic of China), ⁴National Taiwan University Hospital Hsinchu Branch, Hsinchu City, Taiwan, ⁵Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan, Taipei, Taiwan (Republic of China), ⁶Department of Internal Medicine, National Taiwan University Hospital Yun-Lin Branch, Yun-Lin, Taiwan, Taipei, Taiwan (Republic of China), ⁷Department of Nuclear Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan., Taipei, Taiwan (Republic of China), ⁸Department of Nuclear Medicine, National Taiwan University Hospital, Taipei, Taiwan., Taipei, Taiwan (Republic of China), ⁹Department of Ophthalmology, National Taiwan University Hospital, Taipei City, Taiwan., Taipei, Taiwan (Republic of China), ¹⁰Department of Internal Medicine, National Taiwan University Cancer Center, Taipei, Taiwan, Taipei, Taiwan (Republic of China), ¹¹National Taiwan University Hospital, Taipei, Taiwan, ¹²National Taiwan Unuversity Hospital, Taipei City, Taiwan (Republic of China)
Background/Purpose: In primary Sjögren’s syndrome (pSS), the histologic focus score reflects immune infiltration but does not capture irreversible glandular damage. We evaluated a submandibular gland…
Abstract Number: 2525 • ACR Convergence 2025
Point-of-Care Risk Factors for Systemic Disease in Patients Presenting with Small Vessel Vasculitis of the Skin
Arjun Mahajan¹, William Song², Andrew Walls³, Arash Mostaghimi³, Robert Micheletti² and Evan Piette³, ¹Harvard Medical School, Boston, ²Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ³Brigham and Women's Hospital, Harvard Medical School, Boston
Background/Purpose: Small vessel vasculitis (SVV) presenting in the skin may be skin-limited or a manifestation of systemic vasculitis or an underlying autoimmune disease. However, no…
Abstract Number: 1126 • ACR Convergence 2025
Clinical Impact of Signs of Calcium Pyrophosphate Deposition Disease (CPPD) on Radiographs of Hands and Wrists in a Real-World Cohort of Patients with Early Rheumatoid Arthritis
Coralie Tremblay¹, Nathalie Carrier², Hugues Allard-Chamard³, Javier Marrugo⁴, Sophie Roux⁴, Gilles Boire⁵ and Ariel Masetto⁴, ¹Université de Sherbrooke, Division of Rheumatology, Department of Medicine and Health Sciences, Sherbrooke, Canada, and Centre intégré universitaire de santé et de services sociaux de l’Estrie – Centre hospitalier universitaire de Sherbrooke (CIUSSS de l’Estrie – CHUS), Sherbrooke, Canada, Saint-Augustin-de-Desmaures, QC, Canada, ²Centre integré universitaire de santé et de services sociaux de l’Estrie – Centre hospitalier universitaire de Sherbrooke (CIUSSS de l’Estrie-CHUS), Sherbrooke, Canada, ³Université de Sherbrooke, Sherbrooke, Canada, ⁴Université de Sherbrooke, Division of Rheumatology, Department of Medicine and Health Sciences, Sherbrooke, Canada, and Centre intégré universitaire de santé et de services sociaux de l’Estrie – Centre hospitalier universitaire de Sherbrooke (CIUSSS de l’Estrie – CHUS), Sherbrooke, Canada, Sherbrooke, Canada, ⁵Retired, Sherbrooke, QC, Canada
Background/Purpose: Calcium pyrophosphate deposition disease (CPPD) is a common cause of arthropathy over the age of 60. It can also manifest as a chronic polyarticular…
Abstract Number: 0288 • ACR Convergence 2025
Predictors and Characteristics of Objective Flares in Adult Dermatomyositis
Didem Saygin¹, York Wang², Kathryn C. Fitzgerald³, Jemima Albayda⁴, Julie Paik⁵, Eleni Tiniakou⁶, Brittany L Adler², Andrew Mammen⁷, Lisa Christopher-Stine⁴ and Chris Mecoli², ¹Rush University Medical Center, Chicago, IL, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, ⁴Johns Hopkins University, Baltimore, MD, ⁵Johns Hopkins Rheumatology, Baltimore, MD, ⁶UT Health Science Houston, Houston, TX, ⁷NIH, Bethesda, MD
Background/Purpose: Dermatomyositis (DM) is a chronic systemic autoimmune disease with a heterogenous clinical course. Flares often lead to increased morbidity, health care utilization, and reduced…
Abstract Number: 2382 • ACR Convergence 2025
Autoimmune Hemolytic Anemia in SLE: A Real-World National Cohort Study
Bana Shawareb¹, Muhannad Haddadin¹, lindsay Frumker², Keri Ann Pfeil³, Meghan Gump³, Ansaam Daoud⁴ and Omer Pamuk⁵, ¹Cleveland Clinic Akron General, Akron, OH, ²Case Western Reserve University, Cleveland, ³University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH, ⁴Case Western Reserve University/University Hospitals, Cleveland, OH, ⁵University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH
Background/Purpose: Autoimmune hemolytic anemia (AIHA) is a rare but serious hematologic manifestation of SLE. The prognostic implications of AIHA, particularly long-term mortality and organ involvement,…
Abstract Number: 0688 • ACR Convergence 2025
Total lung capacity is predictive of disease severity and survival in systemic sclerosis: a longitudinal analysis in 2347 patients from the French National Cohort Study
Benjamin Chaigne¹, Alexandre bense², Frédérique Aubourg³, Christian AGARD⁴, Yannick Allanore⁵, Alice berezne¹, Gregory Pugnet⁶, Eric Hachulla⁷, Vincent Cottin⁸, Arnaud Hot⁸, bertrand Dunogue¹, Anuxcy Kanagaratnam², Sylvain Palat⁹, Alain Lescoat¹⁰, Sabine berthier¹¹, Emmanuel Chatelus¹², Sébastien Rivière¹³, David Launay¹⁴, Marie-Elise Truchetet¹⁵, Anh-Tuan Dinh-Xuan³ and Luc Mouthon¹, ¹Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin University Hospital, Université Paris Cité, AP-HP, Paris, France, ²AP HP, Paris, France, ³Unité exploration fonctionnelle respiratoire, Pneumology department, Cochin Hospital, APHP, PARIS, France, ⁴Internal medicine, Nantes University Hospital, Nantes, France, ⁵Université Paris Cité, Paris, France, ⁶CHU, Montpelliers, France, ⁷CHU, Lilles, France, ⁸CHU, Lyon, France, ⁹Limoges, Limoges, France, ¹⁰CHU Rennes - University Rennes, Rennes, France, ¹¹CHU, Dijon, France, ¹²Department of Rheumatology, University Hospital Strasbourg, France, Strasbourg, France, ¹³AP HP, Parsi, France, ¹⁴Univ. Lille, Inserm, CHU Lille, Department of Internal Medicine and Clinical Immunology, Reference Center for Rare Autoimmune and Autoinflammatory diseases (CERAINOM), U¹²⁸⁶ - INFINITE - Institute for Translational Research in Inflammation, Lille, France. National Reference Center for Pulmonary Arterial Hypertension (Pulmotension), Lille, France, Lille Cedex, France, ¹⁵Bordeaux University Hospital, Bordeaux, France
Background/Purpose: Total lung capacity (TLC) is seldom assessed in the prediction of systemic sclerosis (SSc) disease severity.Herein, we utilized the French SSc national database to…
Abstract Number: 0037 • ACR Convergence 2025
A Proteomic Signature Containing TNF Receptor Superfamily Member 10A (TNFRSF10A) and Growth/Differentiation Factor 15 (GDF-15) Improves Prediction of All-Cause Mortality Among Individuals with Gout, Beyond Atherosclerotic Cardiovascular and Other Clinical Risk Factors
Natalie McCormick¹, Sharan Rai², Chio Yokose³, Tony Merriman⁴, Robert Terkeltaub⁵ and Hyon K. Choi⁶, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital/Harvard Medical School, Boston, MA, ³Massachusetts General Hospital, Waltham, MA, ⁴University of Alabama at Birmingham, Homewood, AL, ⁵Retired, San Diego, CA, ⁶MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA
Background/Purpose: Gout affects >12 million US adults and is associated with premature all-cause and cardiovascular (CV) mortality which has failed to improve over recent decades,…
Abstract Number: 2237 • ACR Convergence 2025
Safety of DMARD therapy in veterans with rheumatoid arthritis following melanoma diagnosis: a survival analysis
Gabriella Girolami¹, Shamey Kassim², Alexander Peterson³, Aaron Baraff³, Alexandra Schmidt³, Shailender Bhatia⁴, Natalie Miller⁴, Jennifer Barton⁵, Jeffrey Curtis⁶, Christopher Li⁴ and Namrata Singh⁷, ¹University of Washington, Seattle, ²University of Washington, Seattle, WA, ³VA Puget Sound Health Care System, Seattle, WA, ⁴Fred Hutch Cancer Center, Seattle, ⁵VA Portland Health Care System/OHSU, Portland, OR, ⁶Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL, ⁷University of Washington, Bellevue, WA
Background/Purpose: While disease-modifying anti-rheumatic drugs (DMARDs) are critical in managing rheumatoid arthritis (RA), their immunosuppressive effects raise concerns about cancer-related outcomes. In patients with RA…
Abstract Number: 0682 • ACR Convergence 2025
Predictors of Severe Outcomes in Scleroderma Renal Crisis: Updated Results from a Single Center Study
Alex Luta¹, Saloni Mitchell² and Virginia Steen³, ¹Hospital for Special Surgery, New York, NY, ²Mount Sinai West and Morningside, New York, NY, ³Georgetown University School of Medicine, Washington, DC
Background/Purpose: Scleroderma Renal Crisis (SRC) is a severe manifestation of Systemic Sclerosis (SSc) associated with elevated morbidity and mortality. We aimed to address the challenges…
Abstract Number: 2086 • ACR Convergence 2025
WOMAC Physical Function and 3D MRI Bone Shape: Advancing a “Virtual” Total Knee Replacement Endpoint for Knee Osteoarthritis Clinical Trials
Dawn McGuire¹, Alan Brett², Neil Segal³, Meghan Miller⁴, David Rosen¹ and Yoshi Kumagai⁵, ¹OrthoTrophix, Inc, Foster City, CA, ²Imorphics, Manchester M²⁰ ²HJ, England, United Kingdom, ³KUMC, Kansa City, KS, ⁴OrthoTrophics, Foster City, CA, ⁵OrthoTrophix, Foster City, CA
Background/Purpose: TPX-100, a peptide derived from matrix extracellular phosphoglycoprotein (MEPE), is in development as a potential disease-modifying osteoarthritis drug (DMOAD) for mild to severe knee…
Abstract Number: 0638 • ACR Convergence 2025
Prevalence of lupus nephritis, end stage kidney disease, avascular necrosis, and mortality in systemic lupus erythematosus in the recent era
Takehiro Nakai¹, Sho Fukui², Yukihiko Ikeda³, Masei Suda⁴, Hiromichi Tamaki¹, mitsumasa kishimoto⁵ and Masato Okada⁶, ¹Immuno-Rheumatology Center, St. Luke’s International Hospital, Tokyo, Japan, ²Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA, ³St Luke's international hospital in Japan, Tokyo, Japan, ⁴Suwa Central Hospital, Nagano, Japan, ⁵Kyorin University School of Medicine, Tokyo, Japan, ⁶St. Luke's International Hospital, Tokyo, Japan
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease associated with an increased risk of chronic kidney disease (CKD), avascular necrosis (AVN), and mortality. Despite…
Abstract Number: 1911 • ACR Convergence 2025
Characterizing Psoriasis Patients at Risk for Transition to Psoriatic Arthritis: Early Insights from the STOP PsA At-Risk Cohort
Victoria Konzett¹, Eva Manger², Simon Reider², Johannes Griss³, Constanze Jonak³, Kastriot Kastrati⁴, Peter Mandl⁴, Gudrun Ratzinger⁵, Christina Duftner², Thomas Karonitsch⁴ and Daniel Aletaha⁶, ¹Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Department of Internal Medicine, Clinical Division of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria, ³Department of Dermatology, Medical University of Vienna, Austria, Vienna, Austria, ⁴Department of Medicine III, Division of Rheumatology, Medical University Vienna, Vienna, Austria, ⁵Department of Dermatology, Venereology and Allergology, Medical University of Innsbruck, Austria, Innsbruck, Austria, ⁶Medical University Vienna, Wien, Austria
Background/Purpose: Psoriatic arthritis (PsA) develops predominantly in patients with psoriasis (Pso). Although key drivers and predictors of disease progression have been identified in recent years,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].